Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

ALZHEIMER DISEASE

Operationalizing the clinical staging scheme in the 2018 NIA–AA research framework

Nature Reviews Neurology volume 17, pages 395–396 (2021)Cite this article

Subjects

The numeric clinical staging scheme in the 2018 NIA–AA research framework reflects the concept that symptoms of Alzheimer disease sit on a continuum rather than falling into distinct clinical categories. A recent study operationalized these clinical stages to evaluate their utility but found limitations in their application.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jack, C. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).

    Article  Google Scholar 

  2. US Food & Drug Administration. Early Alzheimer’s Disease: Developing Drugs for Treatment Guidance for Industry. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alzheimers-disease-developing-drugs-treatment-guidance-industy (2018).

  3. Petersen, R. et al. NIA-AA Alzheimer’s Disease Framework: clinical characterization of stages. Ann. Neurol. https://doi.org/10.1002/ana.26071 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cummings, J. NIA-AA Framework on Alzheimer’s Disease: application to clinical trials. Alzheimers Dement. 15, 172–178 (2019).

    Article  Google Scholar 

  5. Villemagne, V. et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 12, 357–367 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Rebecca E. Amariglio

Authors
  1. Rebecca E. Amariglio
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Rebecca E. Amariglio.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amariglio, R.E. Operationalizing the clinical staging scheme in the 2018 NIA–AA research framework. Nat Rev Neurol 17, 395–396 (2021). https://doi.org/10.1038/s41582-021-00508-6

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41582-021-00508-6

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing